Cyclophosphamide after transplant reduced GVHD in myeloma patientsNovember 20, 2017Multiple MyelomaCellular Therapy
FDA addresses cell-based regenerative medicine in comprehensive new policyNovember 16, 2017Business of MedicineCellular TherapyFDA Actions
Anidulafungin effectively treated invasive pediatric candidiasis in open-label trialOctober 5, 2017PediatricsPatient & Survivor CareCellular Therapy
Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse eventsSeptember 20, 2017Cellular Therapy
Off-the-shelf T cells used to treat viral infections after HSCTAugust 16, 2017Cellular TherapyPatient & Survivor Care
ALLOZITHRO trial: HSCT patients fared worse with azithromycinAugust 8, 2017Cellular TherapyPatient & Survivor Care
Alopecia may be permanent in one in four pediatric HSCT patientsAugust 2, 2017PediatricsPatient & Survivor CareCellular Therapy
Ibrutinib becomes first FDA-approved treatment for chronic GVHDAugust 2, 2017Cellular TherapyPatient & Survivor Care
Bone marrow transplantation for epidermolysis bullosa continues to evolveJuly 28, 2017PediatricsCellular Therapy
Allele-matching in cord blood transplant yields better survivalJuly 20, 2017Bleeding DisordersCellular TherapyAnemia
All FDA panel members go thumbs up for CTL019 in relapsed/refractory childhood ALLJuly 12, 2017ALLCellular Therapy
Tool indicates fracture risk after HSCTJuly 10, 2017Multiple MyelomaPatient & Survivor CareCellular Therapy
